$ACAD
ACADIA PHARMACEUTICALS INC

2014 Q1 Form 10-K Financial Statement

#000119312514073040 Filed on February 27, 2014

View on sec.gov

Income Statement

Concept 2014 Q1 2012 Q4 2012 Q3
Revenue $30.00K $380.0K $3.478M
YoY Change -92.81% -35.37% 495.55%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $6.300M $2.300M $1.500M
YoY Change 186.36% 53.33% 0.0%
% of Gross Profit
Research & Development $11.67M $4.900M $4.400M
YoY Change 163.39% 11.36% 5.82%
% of Gross Profit
Depreciation & Amortization $43.00K $20.00K $30.00K
YoY Change 258.33% -33.33% 0.0%
% of Gross Profit
Operating Expenses $17.99M $7.200M $5.885M
YoY Change 173.33% 22.03% 3.66%
Operating Profit -$17.96M -$2.407M
YoY Change 191.34% -52.74%
Interest Expense $130.0K $0.00 $5.000K
YoY Change 217.07%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$17.80M -$6.800M -$2.400M
YoY Change 191.8% 28.3% -52.94%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$17.83M -$6.810M -$2.402M
YoY Change 191.16% 28.49% -52.68%
Net Earnings / Revenue -59426.67% -1792.11% -69.06%
Basic Earnings Per Share
Diluted Earnings Per Share -$191.4K -$112.0K -$44.53K
COMMON SHARES
Basic Shares Outstanding 91.35M shares 56.62M shares 53.03M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2014 Q1 2012 Q4 2012 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $369.3M $108.0M $23.10M
YoY Change 263.83% 248.28% -36.19%
Cash & Equivalents $96.46M $57.90M $8.016M
Short-Term Investments $272.8M $50.07M $15.00M
Other Short-Term Assets $1.900M $600.0K $600.0K
YoY Change 26.67% -33.33% 0.0%
Inventory
Prepaid Expenses $1.893M
Receivables
Other Receivables
Total Short-Term Assets $372.8M $108.5M $23.69M
YoY Change 262.01% 239.75% -35.64%
LONG-TERM ASSETS
Property, Plant & Equipment $543.0K $42.00K $63.00K
YoY Change 1710.0% -72.19% -68.5%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $143.0K $0.00 $2.000K
YoY Change -100.0% -98.0%
Total Long-Term Assets $686.0K $42.00K $65.00K
YoY Change 2186.67% -74.55% -67.5%
TOTAL ASSETS
Total Short-Term Assets $372.8M $108.5M $23.69M
Total Long-Term Assets $686.0K $42.00K $65.00K
Total Assets $373.5M $108.6M $23.75M
YoY Change 262.57% 238.14% -35.81%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.562M $1.375M $1.131M
YoY Change 11.89% -29.85% -13.0%
Accrued Expenses $6.429M $4.139M $4.686M
YoY Change 54.58% 18.12% 6.5%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $0.00
YoY Change -100.0%
Total Short-Term Liabilities $8.033M $5.948M $6.086M
YoY Change 41.05% -3.52% -4.91%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00 $17.70M $0.00
YoY Change -100.0% 580.77% -100.0%
Total Long-Term Liabilities $13.00K $17.70M $0.00
YoY Change -99.93% 580.77% -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $8.033M $5.948M $6.086M
Total Long-Term Liabilities $13.00K $17.70M $0.00
Total Liabilities $8.046M $5.948M $6.086M
YoY Change -65.62% -32.04% -31.62%
SHAREHOLDERS EQUITY
Retained Earnings -$423.5M -$367.7M -$360.9M
YoY Change 13.28% 6.01%
Common Stock $10.00K $7.000K $6.000K
YoY Change 42.86% 40.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $365.5M $84.98M $17.66M
YoY Change
Total Liabilities & Shareholders Equity $373.5M $108.6M $23.75M
YoY Change 262.57% 238.14% -35.81%

Cashflow Statement

Concept 2014 Q1 2012 Q4 2012 Q3
OPERATING ACTIVITIES
Net Income -$17.83M -$6.810M -$2.402M
YoY Change 191.16% 28.49% -52.68%
Depreciation, Depletion And Amortization $43.00K $20.00K $30.00K
YoY Change 258.33% -33.33% 0.0%
Cash From Operating Activities -$14.18M -$6.290M -$5.310M
YoY Change 115.34% 17.79% 27.34%
INVESTING ACTIVITIES
Capital Expenditures $6.000K
YoY Change
Acquisitions
YoY Change
Other Investing Activities -$99.11M -$35.06M -$2.740M
YoY Change 199.52% -1020.21% -161.16%
Cash From Investing Activities -$99.11M -$35.06M -$2.740M
YoY Change 199.55% -1020.21% -161.16%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $196.8M $6.800M
YoY Change 94515.38%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 198.0M 91.23M 6.860M
YoY Change 95111.54% 101266.67% -68700.0%
NET CHANGE
Cash From Operating Activities -14.18M -6.290M -5.310M
Cash From Investing Activities -99.11M -35.06M -2.740M
Cash From Financing Activities 198.0M 91.23M 6.860M
Net Change In Cash 84.75M 49.88M -1.190M
YoY Change -314.76% -3563.89% -496.67%
FREE CASH FLOW
Cash From Operating Activities -$14.18M -$6.290M -$5.310M
Capital Expenditures $6.000K
Free Cash Flow -$14.19M
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2006Q4 acad Milestones Payable
MilestonesPayable
10500000
CY2011Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
0.35 shares
CY2011Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights
1.38
CY2014Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
91348503 shares
CY2013Q2 dei Entity Public Float
EntityPublicFloat
1000000000
CY2010Q4 us-gaap Stockholders Equity
StockholdersEquity
29688000
CY2010Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6849000
CY2011Q4 us-gaap Stockholders Equity
StockholdersEquity
23362000
CY2011Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6889000
CY2012Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
5347137 shares
CY2012Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
73334216 shares
CY2012Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.08
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6948456 shares
CY2012Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2012Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2012Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights
0.01
CY2012Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.0001
CY2012Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2012Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
5347137 shares
CY2012Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2012Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
500000 shares
CY2012Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2012Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
73334216 shares
CY2012Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2012Q4 us-gaap Liabilities Current
LiabilitiesCurrent
5948000
CY2012Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
4000
CY2012Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2012Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
413000
CY2012Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4733000
CY2012Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
146000
CY2012Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
452693000
CY2012Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1375000
CY2012Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
364000
CY2012Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
146706000
CY2012Q4 us-gaap Stockholders Equity
StockholdersEquity
84984000
CY2012Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-367720000
CY2012Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
434000
CY2012Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2012Q4 us-gaap Temporary Equity Redemption Value
TemporaryEquityRedemptionValue
17658000
CY2012Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4139000
CY2012Q4 us-gaap Liabilities
Liabilities
5948000
CY2012Q4 us-gaap Common Stock Value
CommonStockValue
7000
CY2012Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
108590000
CY2012Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
127894000
CY2012Q4 us-gaap Investment Owned At Fair Value
InvestmentOwnedAtFairValue
56382000
CY2012Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
50068000
CY2012Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
146706000
CY2012Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
2906000
CY2012Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
4075000
CY2012Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
CY2012Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
4775000
CY2012Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
775000
CY2012Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
42000
CY2012Q4 us-gaap Assets
Assets
108590000
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
57899000
CY2012Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
11056000
CY2012Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
56382000
CY2012Q4 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
107598000
CY2012Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
581000
CY2012Q4 us-gaap Assets Current
AssetsCurrent
108548000
CY2012Q4 acad Class Of Warrant Or Right Issued
ClassOfWarrantOrRightIssued
500000 shares
CY2012Q4 acad Accrued Clinical Development Services
AccruedClinicalDevelopmentServices
3216000
CY2012Q4 acad Available For Sale Securities Gross Unrealized Gain Accumulated In Investments
AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments
5000
CY2012Q4 acad Available For Sale Securities Gross Unrealized Loss Accumulated In Investments
AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments
5000
CY2013Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0 shares
CY2013Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
91102618 shares
CY2013Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
4314480 shares
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.81
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7338138 shares
CY2013Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2013Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
6.53
CY2013Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.0001
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
3.79
CY2013Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2013Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
0 shares
CY2013Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2013Q4 us-gaap Class Of Warrant Or Right Unissued
ClassOfWarrantOrRightUnissued
1965968 shares
CY2013Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
7034407 shares
CY2013Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
91102618 shares
CY2013Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2013Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
838000
CY2013Q4 us-gaap Liabilities Current
LiabilitiesCurrent
6979000
CY2013Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
48000
CY2013Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2013Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1865000
CY2013Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1974000
CY2013Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
172000
CY2013Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
587742000
CY2013Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
2287000
CY2013Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
372000
CY2013Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
308000
CY2013Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
CY2013Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
160241000
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
182131000
CY2013Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-405668000
CY2013Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
55000
CY2013Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2013Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6552000
CY2013Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
866000
CY2013Q4 us-gaap Liabilities
Liabilities
6987000
CY2013Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
583000
CY2013Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
8000
CY2013Q4 us-gaap Common Stock Value
CommonStockValue
9000
CY2013Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
189118000
CY2013Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
179000
CY2013Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
136583000
CY2013Q4 us-gaap Investment Owned At Fair Value
InvestmentOwnedAtFairValue
174083000
CY2013Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
174083000
CY2013Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
160241000
CY2013Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
3221000
CY2013Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
8003000
CY2013Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
CY2013Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2553000
CY2013Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
1207000
CY2013Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
579000
CY2013Q4 us-gaap Assets
Assets
189118000
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
11707000
CY2013Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
11227000
CY2013Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
91500000
CY2013Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
174038000
CY2013Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
20000000
CY2013Q4 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
185831000
CY2013Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2570000
CY2013Q4 us-gaap Assets Current
AssetsCurrent
188360000
CY2013Q4 acad Warrant To Purchase Common Stock
WarrantToPurchaseCommonStock
1465968 shares
CY2013Q4 acad Federal Research And Development Credit Carryforwards
FederalResearchAndDevelopmentCreditCarryforwards
8000000
CY2013Q4 acad Operating Leases Future Minimum Payments Due In Five Years And Thereafter
OperatingLeasesFutureMinimumPaymentsDueInFiveYearsAndThereafter
CY2013Q4 acad Accrued Clinical Development Services
AccruedClinicalDevelopmentServices
4207000
CY2013Q4 acad Available For Sale Securities Gross Unrealized Gain Accumulated In Investments
AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments
59000
CY2013Q4 acad Available For Sale Securities Gross Unrealized Loss Accumulated In Investments
AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments
14000
CY2013Q2 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
9200000 shares
CY2013Q2 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
107900000
CY2012Q4 us-gaap Fair Value Assumptions Expected Volatility Rate
FairValueAssumptionsExpectedVolatilityRate
1.058 pure
CY2012Q4 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
19000000 shares
CY2012Q4 us-gaap Fair Value Assumptions Risk Free Interest Rate
FairValueAssumptionsRiskFreeInterestRate
0.011 pure
CY2012Q4 us-gaap Equity Issuance Per Share Amount
EquityIssuancePerShareAmount
4.43
CY2012Q4 us-gaap Fair Value Assumptions Expected Term
FairValueAssumptionsExpectedTerm
P7Y
CY2012Q4 acad Issuance Of Warrants Price Per Share
IssuanceOfWarrantsPricePerShare
4.42
CY2012Q4 acad Warrants Expiration Date
WarrantsExpirationDate
2019-12-17
CY2012Q4 acad Description Of Warrant
DescriptionOfWarrant
Per their terms, the outstanding warrants to purchase 500,000 shares of common stock may not be exercised if the holder's ownership of the Company's common stock would exceed 19.99 percent following such exercise.
CY2012Q4 acad Issuance Of Warrants Value
IssuanceOfWarrantsValue
2200000
CY2011Q2 us-gaap Stock Issued During Period Shares Other
StockIssuedDuringPeriodSharesOther
782339 shares
CY2012Q4 acad Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
80500000
CY2011Q2 us-gaap Cumulative Translation Adjustment Net Of Tax Period Increase Decrease
CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease
539000
CY2011Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1100000
CY2011Q2 acad Payments On Facility Lease Obligations
PaymentsOnFacilityLeaseObligations
690000
CY2011Q2 acad Lease Termination Costs
LeaseTerminationCosts
1700000
CY2005Q2 acad Operating Lease Term
OperatingLeaseTerm
P10Y
CY2011Q1 us-gaap Fair Value Assumptions Expected Volatility Rate
FairValueAssumptionsExpectedVolatilityRate
0.990 pure
CY2011Q1 us-gaap Fair Value Assumptions Expected Dividend Rate
FairValueAssumptionsExpectedDividendRate
0.00 pure
CY2011Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
12565446 shares
CY2011Q1 us-gaap Fair Value Assumptions Risk Free Interest Rate
FairValueAssumptionsRiskFreeInterestRate
0.028 pure
CY2011Q1 us-gaap Equity Issuance Per Share Amount
EquityIssuancePerShareAmount
1.19375
CY2011Q1 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
1 shares
CY2011Q1 us-gaap Fair Value Assumptions Expected Term
FairValueAssumptionsExpectedTerm
P7Y
CY2011Q1 acad Warrants Expiration Date
WarrantsExpirationDate
2018-01-11
CY2011Q1 acad Issuance Of Warrants Value
IssuanceOfWarrantsValue
3300000
CY2011Q1 acad Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
13900000
CY2011 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-19897000
CY2011 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
52183000 shares
CY2011 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.25
CY2011 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9973000 shares
CY2011 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.44
CY2011 us-gaap Stock Issued During Period Shares Employee Stock Purchase Plans
StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
189879 shares
CY2011 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3000
CY2011 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
9000
CY2011 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
13000
CY2011 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-106000
CY2011 us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
48066000
CY2011 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
87000
CY2011 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-512000
CY2011 us-gaap Revenues
Revenues
2067000
CY2011 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
131000
CY2011 us-gaap Repayments Of Long Term Debt And Capital Securities
RepaymentsOfLongTermDebtAndCapitalSecurities
78000
CY2011 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-23268000
CY2011 us-gaap Operating Income Loss
OperatingIncomeLoss
-22852000
CY2011 us-gaap Unrealized Gain Loss On Securities
UnrealizedGainLossOnSecurities
9000
CY2011 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
1322000
CY2011 us-gaap Net Income Loss
NetIncomeLoss
-22765000
CY2011 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-105000
CY2011 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-503000
CY2011 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
109000
CY2011 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1598000
CY2011 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
13944000
CY2011 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7610000
CY2011 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
8820000
CY2011 us-gaap Share Based Compensation
ShareBasedCompensation
1598000
CY2011 us-gaap Depreciation And Amortization
DepreciationAndAmortization
285000
CY2011 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
40000
CY2011 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
2100000
CY2011 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
5980000
CY2011 us-gaap Other Noncash Expense
OtherNoncashExpense
806000
CY2011 us-gaap Operating Expenses
OperatingExpenses
24919000
CY2011 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
368000
CY2011 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
17000
CY2011 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
13000
CY2011 us-gaap Income Tax Reconciliation Nondeductible Expense Research And Development
IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment
-514000
CY2011 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-57000
CY2011 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
6000
CY2011 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
277000
CY2011 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-1288000
CY2011 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-29000
CY2011 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
14022000
CY2011 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-7734000
CY2011 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-92000
CY2011 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
54049000
CY2011 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
59000
CY2011 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
17309000
CY2011 us-gaap Deferred Compensation Arrangement With Individual Employer Contribution
DeferredCompensationArrangementWithIndividualEmployerContribution
156000
CY2011 acad Income Tax Expense Permanent Tax Differences
IncomeTaxExpensePermanentTaxDifferences
306000
CY2011 acad Stock Issued During Period Value Common Stock Warrants
StockIssuedDuringPeriodValueCommonStockWarrants
13900000
CY2011 acad Stock Issued Employee Stock Purchase Plan Average Price Per Share
StockIssuedEmployeeStockPurchasePlanAveragePricePerShare
0.57
CY2013 dei Trading Symbol
TradingSymbol
ACAD
CY2013 dei Entity Registrant Name
EntityRegistrantName
ACADIA PHARMACEUTICALS INC
CY2013 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2013 dei Amendment Flag
AmendmentFlag
false
CY2013 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2013 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2013
CY2013 dei Document Type
DocumentType
10-K
CY2013 dei Document Period End Date
DocumentPeriodEndDate
2013-12-31
CY2013 dei Entity Central Index Key
EntityCentralIndexKey
0001070494
CY2013 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
Yes
CY2013 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2013 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2013 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2013 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
5.04
CY2013 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y1M6D
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
1954500 shares
CY2013 us-gaap Defined Contribution Plan Maximum Annual Contributions Per Employee Percent
DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
0.60 pure
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Requisite Service Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
P10Y
CY2013 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
16.68
CY2013 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-31769000
CY2013 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent
SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
0.15 pure
CY2013 us-gaap Deferred Compensation Arrangement With Individual Description
DeferredCompensationArrangementWithIndividualDescription
Effective January 1997, the Company established a deferred compensation plan (the “401(k) Plan”) pursuant to Section 401(k) of the Internal Revenue Code of 1986, as amended (the “Code”), whereby substantially all employees are eligible to contribute up to 60 percent of their pretax earnings, not to exceed amounts allowed under the Code. The Company makes discretionary contributions to the 401(k) Plan equal to 100 percent of each employee’s pretax contributions up to 5 percent of his or her eligible compensation, subject to limitations under the Code. The Company’s total contributions to the 401(k) Plan were $240,000, $180,000, and $156,000 for the years ended December 31, 2013, 2012 and 2011, respectively.
CY2013 us-gaap Fair Value Assumptions Expected Dividend Rate
FairValueAssumptionsExpectedDividendRate
0.00 pure
CY2013 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y8M12D
CY2013 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
85715000 shares
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
12.66
CY2013 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P7Y
CY2013 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y10M24D
CY2013 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 Segment
CY2013 us-gaap Defined Contribution Plan Employer Matching Contribution Percent Of Match
DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
1.00 pure
CY2013 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
107883000
CY2013 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
618000
CY2013 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
45000
CY2013 us-gaap Income Tax Reconciliation Deductions
IncomeTaxReconciliationDeductions
-2781000
CY2013 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3441000
CY2013 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
179000
CY2013 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
10000
CY2013 us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
211585000
CY2013 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
349000
CY2013 us-gaap Property Plant And Equipment Disposals
PropertyPlantAndEquipmentDisposals
2800000
CY2013 us-gaap Operating Income Loss
OperatingIncomeLoss
-38297000
CY2013 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
1455406 shares
CY2013 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px"><font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Concentrations of Risk</i></b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">Financial instruments, which potentially subject the Company to concentrations of credit risk, principally consist of cash, cash equivalents, and investment securities. The Company currently invests its excess cash primarily in a money market fund, U.S. Treasury notes, and high quality, marketable debt instruments of corporations, financial institutions and government sponsored enterprises. The Company has adopted an investment policy that includes guidelines relative to credit quality, diversification and maturities to preserve principal and liquidity.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">During the years ended December&#xA0;31, 2013, 2012 and 2011, revenues from the Company&#x2019;s agreements with certain collaborative partners exceeded 10 percent of its total revenues. During the year ended December&#xA0;31, 2013, revenues from Allergan, Inc., the National Institutes of Health, and The Michael J. Fox Foundation comprised 50 percent, 19 percent, and 15 percent of total revenues, respectively. During the year ended December&#xA0;31, 2012, revenues from Allergan and Meiji Seika Pharma Co., Ltd. (&#x201C;Meiji Seika Pharma&#x201D;) comprised 23 percent and 66 percent of total revenues, respectively. During the year ended December&#xA0;31, 2011, revenues from Allergan, Meiji Seika Pharma and The Michael J. Fox Foundation comprised 52 percent, 25 percent and 13 percent of total revenues, respectively.</font></p> </div>
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
109412 shares
CY2013 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10361000 shares
CY2013 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px"><font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Use of Estimates</i></b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.</font></p> </div>
CY2013 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.44
CY2013 us-gaap Stock Issued During Period Shares Employee Stock Purchase Plans
StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
122853 shares
CY2013 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.36
CY2013 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
13500000
CY2013 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1000
CY2013 us-gaap Revenues
Revenues
1145000
CY2013 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1989000
CY2013 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-37904000
CY2013 acad Net Shares Reclassified Out Of Mandatorily Redeemable Capital Stock Value
NetSharesReclassifiedOutOfMandatorilyRedeemableCapitalStockValue
17658000
CY2013 acad Deferred Tax Assets Loss Carryforwards Excess Tax Deductions Resulting From Share Based Compensation
DeferredTaxAssetsLossCarryforwardsExcessTaxDeductionsResultingFromShareBasedCompensation
16400000
CY2012 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-21633000
CY2013 us-gaap Unrealized Gain Loss On Securities
UnrealizedGainLossOnSecurities
45000
CY2013 us-gaap Net Income Loss
NetIncomeLoss
-37948000
CY2013 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-1528000
CY2013 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
44000
CY2013 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
358000
CY2013 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5711000
CY2013 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
111682000
CY2013 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12720000
CY2013 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
13509000
CY2013 us-gaap Share Based Compensation
ShareBasedCompensation
5711000
CY2013 us-gaap Depreciation And Amortization
DepreciationAndAmortization
79000
CY2013 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-46192000
CY2013 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
594000
CY2013 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-126104000
CY2013 us-gaap Operating Expenses
OperatingExpenses
39442000
CY2013 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
-223000
CY2013 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2013 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-1000
CY2013 us-gaap Income Tax Reconciliation Nondeductible Expense Research And Development
IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment
-1269000
CY2013 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-379000
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
20700000
CY2013 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
2413000
CY2013 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-2140000
CY2013 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1003000
CY2013 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
111682000
CY2013 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-12902000
CY2013 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
12000
CY2013 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
8000
CY2013 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
3400000
CY2013 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
0
CY2013 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
86087000
CY2013 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
26722000
CY2013 us-gaap Deferred Compensation Arrangement With Individual Employer Contribution
DeferredCompensationArrangementWithIndividualEmployerContribution
240000
CY2013 us-gaap Other Than Temporary Impairment Losses Investments Availableforsale Securities
OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities
0
CY2013 acad Lease Expiration Month And Year
LeaseExpirationMonthAndYear
2016-12
CY2013 acad Stock Issued During Period Shares Stock Warrants Exercised
StockIssuedDuringPeriodSharesStockWarrantsExercised
1643006 shares
CY2013 acad Closing Market Price Of Common Stock
ClosingMarketPriceOfCommonStock
24.99
CY2013 acad Income Tax Expense Permanent Tax Differences
IncomeTaxExpensePermanentTaxDifferences
244000
CY2013 acad Percentage Of Company Matching Contributions To Maximum Each Employees Eligible Compensation
PercentageOfCompanyMatchingContributionsToMaximumEachEmployeesEligibleCompensation
0.05 pure
CY2013 acad Stock Issued Employee Stock Purchase Plan Average Price Per Share
StockIssuedEmployeeStockPurchasePlanAveragePricePerShare
2.92
CY2013 acad Stock Issued During Period Value Stock Warrants Exercised
StockIssuedDuringPeriodValueStockWarrantsExercised
CY2013 acad Class Of Warrant Or Right Exercised
ClassOfWarrantOrRightExercised
1759162 shares
CY2012 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
55116000 shares
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.51
CY2012 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
11256000 shares
CY2012 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.38
CY2012 us-gaap Stock Issued During Period Shares Employee Stock Purchase Plans
StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
205862 shares
CY2012 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-4000
CY2012 us-gaap Temporary Equity Stock Issued During Period Value New Issues
TemporaryEquityStockIssuedDuringPeriodValueNewIssues
17090000
CY2012 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
453000
CY2012 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-14000
CY2012 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
252000
CY2012 us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
56728000
CY2012 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
37000
CY2012 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1000
CY2012 us-gaap Revenues
Revenues
4907000
CY2012 us-gaap Property Plant And Equipment Disposals
PropertyPlantAndEquipmentDisposals
1500000
CY2012 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-320000
CY2012 us-gaap Repayments Of Long Term Debt And Capital Securities
RepaymentsOfLongTermDebtAndCapitalSecurities
32000
CY2012 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-20854000
CY2012 us-gaap Operating Income Loss
OperatingIncomeLoss
-20886000
CY2012 us-gaap Unrealized Gain Loss On Securities
UnrealizedGainLossOnSecurities
-4000
CY2012 us-gaap Net Income Loss
NetIncomeLoss
-20849000
CY2012 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
133000
CY2012 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-5000
CY2012 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
123000
CY2012 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1930000
CY2012 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
98172000
CY2012 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6999000
CY2012 us-gaap Net Shares Reclassified To Mandatorily Redeemable Capital Stock Value
NetSharesReclassifiedToMandatorilyRedeemableCapitalStockValue
17658000
CY2012 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
8375000
CY2012 us-gaap Share Based Compensation
ShareBasedCompensation
1930000
CY2012 us-gaap Depreciation And Amortization
DepreciationAndAmortization
109000
CY2012 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
51010000
CY2012 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
663000
CY2012 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-25528000
CY2012 us-gaap Operating Expenses
OperatingExpenses
25793000
CY2012 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
616000
CY2012 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2012 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-1000
CY2012 us-gaap Income Tax Reconciliation Nondeductible Expense Research And Development
IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment
-937000
CY2012 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-2822000
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
650000
CY2012 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
635000
CY2012 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-1171000
CY2012 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-585000
CY2012 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
98204000
CY2012 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-7088000
CY2012 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
252000
CY2012 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
30948000
CY2012 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
-4000
CY2012 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
18794000
CY2012 us-gaap Deferred Compensation Arrangement With Individual Employer Contribution
DeferredCompensationArrangementWithIndividualEmployerContribution
180000
CY2012 us-gaap Other Than Temporary Impairment Losses Investments Availableforsale Securities
OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities
0
CY2012 acad Stock Issued During Period Shares Stock Warrants Exercised
StockIssuedDuringPeriodSharesStockWarrantsExercised
874719 shares
CY2012 acad Income Tax Expense Permanent Tax Differences
IncomeTaxExpensePermanentTaxDifferences
209000
CY2012 acad Stock Issued During Period Value Common Stock Warrants
StockIssuedDuringPeriodValueCommonStockWarrants
80538000
CY2012 acad Stock Issued Employee Stock Purchase Plan Average Price Per Share
StockIssuedEmployeeStockPurchasePlanAveragePricePerShare
0.60
CY2012 acad Stock Issued During Period Value Stock Warrants Exercised
StockIssuedDuringPeriodValueStockWarrantsExercised
CY2012 acad Class Of Warrant Or Right Exercised
ClassOfWarrantOrRightExercised
1172774 shares
CY2013Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.08
CY2013Q1 us-gaap Revenues
Revenues
417000
CY2013Q1 us-gaap Net Income Loss
NetIncomeLoss
-6123000
CY2012Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.12
CY2012Q1 us-gaap Revenues
Revenues
450000
CY2012Q1 us-gaap Net Income Loss
NetIncomeLoss
-6218000
CY2012Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.10
CY2012Q2 us-gaap Revenues
Revenues
599000
CY2012Q2 us-gaap Net Income Loss
NetIncomeLoss
-5419000
CY2013Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.11
CY2013Q2 us-gaap Revenues
Revenues
451000
CY2013Q2 us-gaap Net Income Loss
NetIncomeLoss
-9081000
CY2012Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.04
CY2012Q3 us-gaap Revenues
Revenues
3478000
CY2012Q3 us-gaap Net Income Loss
NetIncomeLoss
-2402000
CY2013Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.12
CY2013Q3 us-gaap Revenues
Revenues
240000
CY2013Q3 us-gaap Net Income Loss
NetIncomeLoss
-10695000
CY2012Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.11
CY2012Q4 us-gaap Revenues
Revenues
380000
CY2012Q4 us-gaap Net Income Loss
NetIncomeLoss
-6810000
CY2013Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.13
CY2013Q4 us-gaap Revenues
Revenues
37000
CY2013Q4 us-gaap Net Income Loss
NetIncomeLoss
-12049000

Files In Submission

Name View Source Status
0001193125-14-073040-index-headers.html Edgar Link pending
0001193125-14-073040-index.html Edgar Link pending
0001193125-14-073040.txt Edgar Link pending
0001193125-14-073040-xbrl.zip Edgar Link pending
acad-20131231.xml Edgar Link completed
acad-20131231.xsd Edgar Link pending
acad-20131231_cal.xml Edgar Link unprocessable
acad-20131231_def.xml Edgar Link unprocessable
acad-20131231_lab.xml Edgar Link unprocessable
acad-20131231_pre.xml Edgar Link unprocessable
d652667d10k.htm Edgar Link pending
d652667dex1013.htm Edgar Link pending
d652667dex1015.htm Edgar Link pending
d652667dex211.htm Edgar Link pending
d652667dex231.htm Edgar Link pending
d652667dex311.htm Edgar Link pending
d652667dex312.htm Edgar Link pending
d652667dex321.htm Edgar Link pending
d652667dex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending